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Abstract
Local glucocorticoid (GC) action depends on intracellular GC metabolism by 11β-hydroxysteroid
dehydrogenases (11βHSDs). 11βHSD1 activates GCs, while 11βHSD2 inactivates GCs. Adipocyte-
specific amplification of GCs through transgenic overexpression of 11βHSD1 produces visceral
obesity and the metabolic syndrome in mice. To determine whether adipocyte-specific inactivation
of GCs protects against this phenotype, we created a transgenic model in which human 11βHSD2 is
expressed under the control of the murine adipocyte fatty acid binding protein (aP2) promoter (aP2-
h11βHSD2). Transgenic mice have increased 11βHSD2 expression and activity exclusively in
adipose tissue, with the highest levels in subcutaneous adipose tissue, while systemic indexes of GC
exposure are unchanged. Transgenic mice resist weight gain on high-fat diet due to reduced fat mass
accumulation. This improved energy balance is associated with decreased food intake, increased
energy expenditure, and improved glucose tolerance and insulin sensitivity. Adipose tissue gene
expression in transgenic mice is characterized by decreased expression of leptin and resistin and
increased expression of adiponectin, peroxisome proliferator–activated receptor γ, and uncoupling
protein 2. These data suggest that reduction of active GCs exclusively in adipose tissue is an important
determinant of a favorable metabolic phenotype with respect to energy homeostasis and the metabolic
syndrome.
Glucocorticoids (GCs) play a critical role in multiple metabolic processes, including glucose
homeostasis, insulin sensitivity, lipid metabolism, and adipogenesis. GC excess, whether
endogenous (Cushing's syndrome) or exogenous, promotes visceral obesity, insulin resistance,
dyslipidemia, and hypertension (1). A similar constellation of metabolic abnormalities is
associated with idiopathic obesity and defines the much more prevalent metabolic syndrome
(1,2). While subtle alterations in the hypothalamic-pituitary-adrenal axis have been reported
in idiopathic obesity and the metabolic syndrome, no clear role for increased circulating GCs
has been established (3).
GC action in target tissues, however, not only depends on circulating GC concentrations and
cellular GC receptor (GR) expression but also on tissue-specific intracellular GC metabolism
by 11β-hydroxysteroid dehydrogenases (11βHSDs) (4). 11βHSDs act at the prereceptor level
to catalyze the interconversion of hormonally active 11β-hydroxylated GCs (cortisol in human
and corticosterone in mice) and their hormonally inactive 11β-keto metabolites (cortisone in
humans and 11-dehydrocorticosterone [11DHC] in mice) (5). Two isoforms of 11βHSD have
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been identified. 11βHSD1 is a low-affinity NADPH-dependent reductase expressed primarily
in GC target tissues, such as liver, adipose tissue, and the central nervous system, where it
amplifies local GC action. 11βHSD2 is a high-affinity NAD-dependent dehydrogenase
expressed primarily in mineralocorticoid target tissues, such as kidney, where it potently
decreases local GC action, thus ensuring that only the nonsubstrate aldosterone can access
intrinsically nonselective mineralocorticoid receptors (6,7).
Evidence is rapidly accumulating to support a role for 11βHSD1 in the pathogenesis of visceral
obesity and the metabolic syndrome. 11βHSD1 is decreased in liver and enhanced in mesenteric
adipose tissue (MAT) in several models of rodent obesity, including leptin-resistant Leprfa/
Leprfa rats (8,9) and leptin-deficient Lepob/Lepob mice (10). Several studies have shown that
11βHSD1 activity and expression in subcutaneous adipose tissue (SCAT) are positively
correlated with obesity and insulin resistance in both men and women (11–17). In addition,
polymorphic variability at the 11βHSD1 locus is associated with increased waist-to-hip ratio
in adults (18) and with body composition and insulin resistance in children (19).
As such, 11βHSD1 has been proposed as a novel therapeutic target for the treatment of obesity
and the metabolic syndrome. Indeed, pharmacologic inhibition of 11βHSD1 in obese rodents
improves glucose tolerance, insulin sensitivity, and lipid profiles (20–22). While such
treatment is associated with alterations in hepatic gene expression, adipose tissue has not been
evaluated (20,21). Similarly, mice with targeted disruption of 11βHSD1 in all tissues have
reduced weight gain on high-fat diet (HFD), attenuated gluconeogenic response to fasting,
improved glucose tolerance and insulin sensitivity, and atheroprotective lipid profiles, despite
having modestly elevated serum corticosterone levels (23–25). This favorable metabolic
phenotype is associated with improved GC-related metabolic functions in both liver (24) and
adipose tissue (25). Nevertheless, both pharmacologic inhibition and targeted gene deletion of
11βHSD1 affect all tissues, and, hence, the relative contribution of any individual tissue to
overall metabolic phenotype is unclear.
Transgenic mouse models have provided insight into the role of 11βHSD1 in individual tissues.
Mice with adipocyte-specific overexpression of 11βHSD1 driven by the murine adipocyte fatty
acid binding protein (aP2) promoter develop visceral obesity and the metabolic syndrome
(10,26). In contrast, mice with liver-specific overexpression of 11βHSD1 driven by the human
apolipoprotein E promoter develop insulin resistance, dyslipidemia, and hypertension without
obesity (27). These data suggest that GC amplification in adipose tissue, more than liver,
contributes to overall energy balance. Whether 11βHSD1 in adipose tissue contributes to the
other features of the metabolic syndrome, independent of liver, is unknown. Furthermore, the
phenotypic consequences of inhibition or absence of GC regeneration by 11βHSD1 exclusively
in adipose tissue has not been explored.
We hypothesized that a reduction of active GCs exclusively in adipose tissue is an important
determinant of a favorable metabolic phenotype with respect to energy homeostasis and
features of the metabolic syndrome. To test this hypothesis, we generated an animal model of
adipocyte-specific GC inactivation through ectopic overexpression of h11βHSD2 under the
control of the murine aP2 promoter.
Research Design and Methods
Generation of the aP2-h11βHSD2 construct and transgenic mice
A 5.4-kb fragment corresponding to position −5.4 to +21 of the murine aP2 promoter (provided
by B.M. Spiegelman) was ligated to a 1.9-kb fragment corresponding to position −133 to
+1,764 of human placental 11βHSD2 cDNA, including its native polyadenylation signal (28,
29). The linearized 7.3-kb NotI-SalI aP2-h11βHSD2 construct was injected into pronuclei of
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fertilized zygotes from FVB mice and transferred to pseudopregnant females. Offspring were
screened for genomic integration by PCR of tail DNA using the following h11βHSD2-specific
primers: forward 5′-CGGCCGTGGCGCTACT-CAT, reverse 5′-
GGGAAGGGCCGGGGCTCAGGTTT.
Mice were generated by breeding F1 heterozygous transgenic males to wild-type (WT)
females. Experiments were performed in F2 males heterozygous for the transgene. Mice were
housed individually under standard conditions at 25°C with a 14/10-h light-dark cycle and free
access to food and water. Animals were handled in accordance with the guidelines established
by the National Institutes of Health. Procedures were approved by the Animal Care and Use
Committee at the Beth Israel Deaconess Medical Center. For serum corticosterone and thymic
weight, mice were fed chow diet (6% fat wt/wt; Harlan Teklad; RD8664) from 3 to 10 weeks
(n = 8 per group). Ad libitum-fed mice were killed between 9:00 A.M. and 10:00 A.M. under
non-stressed conditions. For other experiments, mice were fed chow diet or HFD (42% fat wt/
wt; Harlan Teklad; TD88137) from 3 to 24 weeks (n = 18–22 per group). Body weight and
food intake were determined weekly. Tail bleeds were performed in fasted mice at 20 weeks.
Intraperitoneal glucose (1 g/kg) and insulin (1.125 units/kg) tolerance tests were performed at
16 and 21 weeks, respectively. At 24 weeks, ad libitum-fed mice were subjected to dual-energy
X-ray absorptiometry (DEXA; Lunar PIXImus mouse densitometer). Mice of each genotype
were subsequently divided into two groups with equal means ± SEs for body weight. One group
(n = 10 per group) was immediately killed by CO2 inhalation. The other group (n = 8 per group)
was placed in a comprehensive laboratory animal monitoring system for measurement of daily
food intake and continuous oxygen consumption (Vo2) for 12 days following a 48-h acclimation
period. At the time the mice were killed, trunk blood was collected by cardiac puncture,
centrifuged, and stored at −20°C. Tissues were weighed, frozen in liquid nitrogen, and stored
at −80°C.
RNA extraction and gene expression analysis
Total RNA was extracted from homogenized tissues using RNeasy Lipid Tissue Mini Kit with
on-column DNAse treatment (Qiagen) followed by generation of cDNA using RETRO-script
(Ambion). Quantitative real-time PCR was performed in triplicate with 1:100 dilution of
cDNA, 1 × Taqman Universal Master Mix (Applied Biosystems), and gene-specific primer-
probe sets using a Stratagene MX4000 Mulitiplex Quantitative PCR System. Reactions were
run at 95°C × 10 min, followed by 40 cycles of 95°C × 15 s and 60°C × 1 min. Sequences for
11βHSD2 and 11βHSD1 primer-probe sets (Biosearch Technologies) were as follows:
h11βHSD2: forward 5′-GGGCCTATGGAACCTCCAA, reverse 5′-GACCCA
CGTTTCTCACTGACTCT, probe 5′-FAM-CCGTGGCGCTACTCATGGACACA-BHQ1;
m11βHSD2: forward 5′-CAGCCTACGGCACCTCCA, reverse 5′-
GCGTTTCTCCCAGAGGTTCA, probe 5′-FAM-TCGGCTGTGAGCTGCTTCCC TGG-
BHQ1; and m11βHSD1: forward 5′-AAGCAGAGCAATGGCAGCAT, reverse 5′-
GAGCAATCATAGGCTGGGTCAT, probe 5′-FAM-CGTCATCTC
CTCCTTGGCTGGGAA-BHQ1. Human- and mouse-specific primers for 11βHSD2 were
tested to confirm that the h11βHSD2 primer-probe set did not amplify m11βHSD2 or vice
versa. Primer-probe sets for other genes were purchased as predesigned Taqman gene
expression assays and run as per the manufacturer's instructions (Applied Biosystems). Gene
expression was determined by the standard curve method and normalized to expression of 18S
RNA (Applied Biosystems). Accuracy of RNA quantification was optimized by DNAse
treatment, gene-specific primer-probe sets that span intron-exon boundaries, and lack of
amplification in no-RT and no-template controls.
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11βHSD1 and 11βHSD2 activity
Activities were assayed as previously described (28,30). 11βHSD2 dehydrogenase activity was
determined by measuring percent conversion of tritiated corticosterone (10 nmol/l) to 11DHC
in the presence of excess (400 μmol/l) enzyme-specific cofactor (NAD+ for 11βHSD2 and
NADPH for 11βHSD1). Reactions contained 0.1 mg/ml protein with an incubation time of 10
min. 11βHSD1 reductase activity was determined in the same way using tritiated 11DHC as
substrate but with 0.2 mg/ml protein and 30-min incubation. Protein concentration and
incubation times were optimized such that activity was in the linear range for product
formation. Reactions were run in duplicate with blank assays run in parallel. Steroids were
extracted with ethyl acetate, separated by thin-layer chromatography, identified by migration
in comparison to known standards, and quantified with a phosphorimager tritium screen (Fuji).
Blood analysis
Plasma glucose was determined using a One Touch FastTake glucometer (LifeScan). Serum
insulin was determined by an Ultra Sensitive Mouse Insulin ELISA Kit (CrystalChem). Serum
corticosterone was determined by a Rat Corticosterone Radioimmunoassay Kit (ICN
Pharmaceuticals).
Statistical analysis
Data are expressed as means ± SE. Comparisons between groups were made by unpaired two-
tailed Student's t tests or by one- or two-way ANOVA, as appropriate with genotype and/or
diet as variables. Where differences were found by ANOVA, post hoc Tukey multiple
comparison tests were performed. For longitudinal body weight and glucose and insulin
tolerance tests, comparisons were made by two-way ANOVA with repeated measures. For
energy expenditure data, comparisons were made using mixed model analysis.
Results
11βHSD2 expression and activity is exclusively increased in adipose tissue of transgenic
mice
Transgenic mice were viable and fertile with progeny in the expected Mendelian ratios. Since
endogenous 11βHSD2 in kidney is sufficient to fully inactivate corticosterone in that tissue,
the goal was to create transgenic mice with murine “kidney” levels of h11βHSD2 in adipose
tissue. Data are shown from a representative line (Fig. 1). The h11βHSD2 transgene was
expressed in all adipose tissue depots of transgenic mice including SCAT, MAT, perigonadal
adipose tissue (PGAT), perirenal plus retroperitoneal adipose tissue (PRRP), intrascapular
white adipose tissue (ISWAT), and brown adipose tissue (BAT) (Fig. 1A). Relative expression
of h11βHSD2 was significantly greater than endogenous m11βHSD1 expression with the ratio
of h11βHSD2 to m11βHSD1 expression in SCAT being 2.55 ± 0.65 and 12.74 ± 4.84 in chow-
and HFD-fed mice, respectively. Expression of h11βHSD2 was absent from nonadipose tissues
of transgenic mice including whole brain, skeletal muscle, liver, and kidney and was also absent
in all of the above tissues of WT mice (data not shown).
Likewise, 11βHSD2 activity was detected in all adipose tissue depots of transgenic mice (Fig.
1B). 11βHSD2 activity in transgenic mice expressed as percent activity in murine kidney was
as follows: transgenic-chow: SCAT 137.73%, BAT 111.35%, PGAT 139.16%, ISWAT
152.72%, and MAT 52.74%; transgenic-HFD: SCAT 246.12%, BAT 87.18%, PGAT
155.36%, ISWAT 168.44%, and MAT 49.74%. 11βHSD2 activity was significantly higher in
transgenic compared with WT mice (Fig. 1C). While endogenous 11βHSD2 has not been
reported in adipocytes per se, low levels have been reported in vascular endothelium (31).
Expression of endogenous m11βHSD2, in contrast to the h11βHSD2 transgene, was extremely
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low relative to murine kidney and was not different between genotypes on a given diet
(m11βHSD2/18S for WT-chow 0.007 ± 0.002, transgenic-chow 0.009 ± 0.002, WT-HFD 0.015
± 0.002, and transgenic-HFD 0.014 ± 0.002), suggesting that the difference in 11βHSD2
activity can be attributed to the h11βHSD2 transgene rather than to endogenous m11βHSD2.
Other determinants of GC action and systemic indexes of GC exposure do not differ between
transgenic and WT mice
11βHSD1 expression (Table 1) and activity (Fig. 1D) in SCAT were similar between WT and
transgenic mice. For both genotypes, 11βHSD1 expression and activity were decreased in mice
on HFD compared with chow diet, consistent with previously published data showing
downregulation of 11βHSD1 by HFD in mice (32). GRα expression (Table 1) in SCAT was
not significantly affected by genotype or diet. In addition, serum corticosterone and various
indexes of systemic GC exposure, including thymic weight, adrenal weight, bone density, lean
body mass, and naso-anal length, were also similar between WT and transgenic mice (Table
2).
Transgenic aP2-h11βHSD2 mice resist weight gain on HFD
Mice of both genotypes fed HFD gained significantly more weight than mice fed chow diet
(body weight at 24 weeks: WT-chow 32.87 ± 0.54 g, transgenic-chow 32.82 ± 0.52 g, WT-
HFD 44.52 ± 0.66 g, and transgenic-HFD 40.80 ± 1.04 g). Body weight for WT and transgenic
mice fed chow diet were similar throughout the 24-week study. In contrast, transgenic mice
fed HFD gained significantly less weight than WT mice fed HFD (Fig. 2).
Transgenic aP2-h11βHSD2 mice on HFD have reduced body fat
Percent fat mass by DEXA (Fig. 3A) was increased in mice of both genotypes fed HFD
compared with mice fed chow diet (WT-chow 20.56 ± 0.57%, transgenic-chow 20.78 ± 0.82%,
WT-HFD 37.78 ± 0.75%, and transgenic-HFD 34.11 ± 1.21%). Percent fat mass by DEXA
was similar between WT and transgenic mice fed chow diet. In contrast, transgenic mice fed
HFD had significantly lower percent fat mass than WT mice fed HFD. Lean body mass by
DEXA and linear growth were not significantly different between genotypes on either diet
(Table 2). Total fat pad weights (Fig. 3B) were increased in mice of both genotypes fed HFD
compared with mice fed chow diet (total fat pad weight: WT-chow 2.70 ± 0.12 g, transgenic-
chow 2.93 ± 0.28 g, WT-HFD 7.38 ± 0.43 g, and transgenic-HFD 5.51 ± 0.55 g). Total fat pad
weights were similar in WT and transgenic mice fed chow diet. In contrast, transgenic mice
fed HFD had significantly lower total fat pad weight than WT mice fed HFD. This difference
in total fat pad weight was primarily due to decreased fat pad weight of the SCAT depot and,
to a lesser extent, the perirenal plus retroperitoneal adipose tissue and ISWAT depots (Fig.
3C).
Transgenic aP2-h11βHSD2 mice have decreased food intake and increased energy
expenditure
Average daily (Fig. 4A) and cumulative (Fig. 4B) food intake were lower in transgenic
compared with WT mice on HFD (average daily food intake for WT-HFD 5.95 ± 0.25 g vs.
transgenic-HFD 5.21 ± 0.23 g; cumulative food intake for WT-HFD 71.40 ± 2.95 g vs.
transgenic-HFD 62.50 ± 2.80 g). In addition, oxygen consumption (Vo2) was significantly
increased in transgenic compared with WT mice (WT-HFD 3,016 ± 34 mg · ml−1 · h−1 vs.
transgenic-HFD 3,238 ± 34 mg · ml−1 · h−1) (Fig. 4C). This elevation in oxygen consumption
in transgenic mice was present throughout the 24-h cycle for each day during the study period
(Fig. 4D).
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Transgenic aP2-h11βHSD2 mice have improved glucose tolerance and insulin sensitivity
Fasting plasma glucose (Fig. 5A) was higher in WT mice fed HFD compared with WT mice
fed chow diet but was not different between transgenic mice fed HFD compared with transgenic
mice fed chow diet (WT-chow 134 ± 7 mg/dl, WT-HFD 155 ± 5 mg/dl; transgenic-chow 137
± 5 mg/dl, transgenic-HFD 148 ± 6 mg/dl). Fasting plasma glucose was not significantly
different between WT and transgenic mice on either diet. Fasting serum insulin (Fig. 5B) was
higher in WT mice fed HFD compared with WT mice fed chow diet but was not different
between transgenic mice fed HFD compared with transgenic mice fed chow diet (WT-chow
0.4190 ± 0.0336 ng/ml, WT-HFD 0.7331 ± 0.0886 ng/ml; transgenic-chow 0.2893 ± 0.0285
ng/ml, transgenic-HFD 0.4350 ± 0.0759 ng/ml). Fasting serum insulin was significantly lower
in transgenic compared with WT mice on both diets.
Glucose tolerance by glucose tolerance test (Fig. 5C) was impaired in WT mice fed HFD
compared with WT mice fed chow diet but was similar in transgenic mice fed HFD versus
transgenic mice fed chow diet. Glucose tolerance was similar between transgenic and WT mice
fed chow diet. Glucose tolerance in transgenic mice fed HFD was improved compared with
WT mice fed HFD and similar to glucose tolerance of mice of both genotypes fed chow diet.
Insulin sensitivity by insulin tolerance test (Fig. 5D) was decreased in WT mice fed HFD
compared with WT mice fed chow diet but was similar in transgenic mice fed HFD versus
transgenic mice fed chow diet. Insulin sensitivity was similar between transgenic and WT mice
fed chow diet. Insulin sensitivity in transgenic mice fed HFD was improved compared with
WT mice fed HFD (initial decrement: WT-HFD +6.3 ± 5.1, transgenic-chow −7.8 ± 3.4 mg/
dl) and similar to insulin sensitivity of mice of both genotypes fed chow diet.
Transgenic aP2-h11βHSD2 mice have a favorable adipose tissue gene expression profile
To evaluate the molecular mechanisms underlying this improved metabolic profile, expression
of genes known to play important roles in adipose tissue metabolism and/or known to be
regulated by GCs were evaluated (Table 1). In the SCAT of transgenic compared with WT
mice fed HFD, expression of soluble phosphenolpyruvate carboxykinase, adiponectin,
peroxisome proliferator-activated receptor γ, and uncoupling protein 2 were significantly
increased, whereas expression of leptin and resistin were significantly decreased. Expression
of tumor necrosis factor-α was also decreased in the SCAT of transgenic compared with WT
mice fed HFD, albeit not significantly so. No significant differences in adipose tissue gene
expression were observed for transgenic compared with WT mice fed chow diet.
DISCUSSION
We describe an animal model of adipocyte-specific GC inactivation through ectopic transgenic
overexpression of h11βHSD2 under the control of the murine aP2 promoter. 11βHSD2
decreases GC action in vivo by catalyzing the unidirectional conversion of hormonally active
11β-hydroxylated GCs to their hormonally inactive 11β-keto metabolites. Since 11βHSD2 is
not endogenously expressed in adipocytes, transgenic overexpression of 11βHSD2 under the
control of the aP2 promoter provides a novel mechanism whereby GC action can be selectively
reduced in adipose tissue, thus reversing the GC-amplifying effect of endogenous 11βHSD1.
A similar approach using ectopic tissue-specific overexpression of 11βHSD2 has been used to
generate an animal model of reduced GC action in hippocampal neurons for the study of
neuronal stress response pathways (33).
Several lines of evidence support adipose tissue–specific GC inactivation in this model. First,
in vitro 11βHSD2 activity data demonstrate increased NAD-dependent dehydrogenation of
corticosterone to its inactive metabolite 11DHC in adipose tissue of transgenic but not WT
mice. This activity is comparable to 11βHSD2 activity in kidney, a level known to be sufficient
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to inactivate GCs and protect mineralocorticoid receptors in the distal nephron where 11βHSD1
is also expressed. Second, endogenous m11βHSD2 is not contributing to this activity since
expression of m11βHSD2 is extremely low in adipose tissue and is not significantly different
between genotypes. Third, no significant differences between genotypes are identified for other
determinants of GC action, including 11βHSD1 expression/activity or GRα expression. Fourth,
expression of the human 11βHSD2 transgene is 2.55- and 12.74-fold greater than expression
of endogenous 11βHSD1 in SCAT of transgenic mice on chow and HFD, respectively. Finally,
a relative increase in GC-repressible genes (i.e., soluble phosphenolpyruvate carboxykinase)
(34,35) and a decrease in GC-inducible genes (i.e., leptin) (36) is observed in transgenic
compared with WT mice fed HFD. Taken together, these data support a net reduction in GC
action in adipose tissue and indicate that the “adipokine” actions of GCs may be key.
Interestingly, 11βHSD2 expression and activity were not uniform among adipose tissue depots.
This finding may suggest the presence of depot-specific regulatory factors that influence the
activity of the aP2 promoter. While MAT has been implicated as the primary determinant of
adverse metabolic consequences associated with the metabolic syndrome (3), most studies in
humans have revealed significant correlations between 11βHSD1 expression/activity in SCAT
and measures of body weight and insulin sensitivity (11–17). Although the greater 11βHSD2
transgene activity in SCAT relative to MAT supports a role for “peripheral” adipose tissue
depots in determining metabolic phenotype in this model, it does not entirely exclude a
substantial contribution by MAT. MAT has relatively higher GR density than other adipose
depots, and such depot-specific differences in GR expression are also important determinants
of local GC action. Furthermore, since endogenous 11βHSD2 is negligible in adipose tissue,
transgenic 11βHSD2, even at very low levels, could have a substantial effect on GC action,
particularly in MAT where GR expression is high. This question could be further explored by
evaluating gene expression in MAT and/or by identifying and evaluating transgenic lines of
aP2-11βHS2 mice with higher 11βHSD2 transgene expression in MAT.
Phenotypic characterization of transgenic aP2-h11βHSD2 mice reveal several similarities with
11βHSD1-deficient mice (23–25). Both models demonstrate an improved metabolic response
to HFD characterized by resistance to diet-induced obesity, reduced fat mass, and improved
glucose tolerance and insulin sensitivity (23–25). In addition, both models have reduced
expression of leptin and resistin and increased expression of adiponectin, peroxisome
proliferator-activated receptor γ, and uncoupling protein 2 in adipose tissue (25). Potential
contributions of these genes to phenotype is discussed in detail elsewhere (25). Hence, these
similarities suggest that altered GC metabolism in adipose tissue is a major contributor to these
aspects of metabolic phenotype.
Nevertheless, there are several important differences between these two models. The major
difference is that local GC inactivation is confined exclusively to adipose tissue in aP2-
h11βHSD2 mice, whereas 11βHSD1-deficient mice have altered GC metabolism in all tissues
expressing the enzyme, including the central nervous system, as well as strain-dependent
modest increases in circulating GCs. In addition, aP2-h11βHSD2 mice have reduced food
intake, while 11βHSD1-deficient mice have increased food intake (25). Leptin, a major
adipocyte-derived hormonal determinant of energy intake, is unlikely to account for this
difference, since adipose tissue leptin expression is similarly reduced in both aP2-h11βHSD2
and 11βHSD1-deficient mice. A more likely explanation is that nonadipocyte-mediated
mechanisms contribute to altered energy intake in 11βHSD1-deficient mice. GCs are well
known to influence appetite and feeding behavior (37,38). Both GRs (39–42) and 11βHSD1
(43,44) are expressed throughout the central nervous system, including several hypothalamic
areas involved in the regulation of energy balance such as the arcuate nucleus (43,44). Whether
primary central 11βHSD1 deficiency or secondary increases in circulating GCs is the main
determinant of altered energy intake in 11βHSD1-deficient mice remains unclear. In contrast,
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the decrease in food intake in aP2-h11βHSD2 mice supports an adipocyte-mediated
mechanism for altered energy intake in this model. This conclusion is further supported by the
opposite observation, i.e., increased food intake, in aP2-h11βHSD1 mice (10). An as yet
unidentified adipocyte-secreted factor may be contributing to the reduced food intake in aP2-
h11βHSD2 mice.
Resistance to diet-induced obesity in aP2-h11βHSD2 mice results not only from decreased
energy intake but also from increased energy expenditure, as indicated by an increase in oxygen
consumption. A similar increase in metabolic rate has been suggested, albeit not proven, in
11βHSD1-deficient mice by an increase in core body temperature (25). For the reasons outlined
above, however, it is difficult to ascertain the relative contribution of central versus peripheral
mechanisms to this altered energy expenditure in 11βHSD1-deficient mice. Increased oxygen
consumption in aP2-h11βHSD2 mice supports an adipocyte-mediated mechanism for altered
energy expenditure. Leptin, which increases energy expenditure, is not the major determinant
of energy expenditure in this model, since leptin expression in adipose tissue is decreased. GCs
decrease thermogenesis (45,46) and inhibit adrenergic stimulation of uncoupling proteins
(47). GCs also inhibit β3 adrenergic receptor signaling and expression (48,49), a major
mechanism promoting thermogenesis in BAT (50). Thus, aP2-h11βHSD2 mice, via decreased
GC action in adipose tissue, would be protected from this GC-mediated inhibition of β3
adrenergic receptors and energy expenditure. Whether the observed level of expression of the
h11βHSD2 transgene in BAT of aP2-h11βHSD2 mice is sufficient to alter β3 adrenergic
receptors gene expression and/or adrenergic stimulation of uncoupling proteins in BAT
remains to be determined. However, data in both aP2-h11βHSD2 and 11βHSD1-deficient mice
suggest that GC metabolism by endogenous 11βHSD1 may play an important role in regulating
GC action in BAT. This question could be further explored by generated BAT-specific models
of increased and decreased GC action via transgenic overexpression of 11βHSD1 and
11βHSD2, respectively
In summary, adipocyte-specific transgenic overexpression of h11βHSD2 has been used as a
strategy to determine the role of adipocyte-specific GC action in systemic energy balance.
Transgenic aP2-h11βHSD2 mice fed HFD exhibit resistance to diet-induced obesity, reduced
fat mass, decreased food intake, increased energy expenditure, and improved glucose tolerance
and insulin sensitivity. This metabolic phenotype is associated with reduced expression of
leptin and resistin, and increased expression of adiponectin, peroxisome proliferator–activated
receptor γ, and uncoupling protein 2 in adipose tissue. These data provide the first in vivo
evidence that reduction of active GCs exclusively in adipose tissue is an important determinant
of a favorable metabolic phenotype with respect to energy homeostasis and the metabolic
syndrome. Further investigation of this model may help to identify novel adipocyte mediators
of systemic energy balance.
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Glossary
11βHSD 11β-hydroxysteroid dehydrogenase
11DHC 11-dehydrocorticosterone
aP2 adipocyte fatty acid binding protein
BAT brown adipose tissue
DEXA dual-energy X-ray absorptiometry
GC glucocorticoid
GR GC receptor
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HFD high-fat diet
ISWAT intrascapular white adipose tissue
MAT mesenteric adipose tissue
PGAT perigonadal adipose tissue
SCAT subcutaneous adipose tissue
WT wild-type
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FIG. 1.
11βHSD2 and 11βHSD1 expression and activity. A: h11βHSD2 expression relative to 18S
RNA in various adipose tissue depots of 24-week-old transgenic and WT mice (n = 10 per
group) using quantitative real-time PCR with human kidney standard curve and a primer-probe
set that detects only human and not murine 11βHSD2. B: 11βHSD2 activity (% conversion
Cort→11DHC) in the above adipose tissue depots and kidney of 24-week-old transgenic mice
(n = 10 per group). 11βHSD2 (C) and 11βHSD1 (D) activity (% conversion 11DHC→Cort)
in SCAT of 24-week-old transgenic and WT mice on chow and HFD (n = 10 per group). Data
are expressed as means ± SE. ***P < 0.001 between genotypes on a given diet; ###P < 0.001
between diet groups for a given genotype.
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FIG. 2.
Body weight. Body weight in transgenic and WT mice fed chow or HFD from 3 to 24 weeks
of age (n = 18–22 per group). □, WT-chow; ○, transgenic-chow; ■, WT-HFD; ●, transgenic-
HFD. Data are expressed as means ± SE. ****P < 0.0001 between genotypes on a given diet;
####P < 0.0001 between diet groups for a given genotype by repeated-measures ANOVA.
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FIG. 3.
Fat mass. A: Percent fat mass by DEXA in 24-week-old transgenic and WT mice fed chow or
HFD (n = 18–22 per group). Total (B) and individual (C) fat pad weights in 24-week-old
transgenic and WT mice fed chow or HFD (n = 10 per group). For individual fat pad weights,
significant differences between diet groups for a given genotype are omitted for clarity. Data
are expressed as means ± SE. *P < 0.05 and **P < 0.01 between genotypes on a given diet;
###P < 0.001 between diet groups for a given genotype.
Kershaw et al. Page 15
Diabetes. Author manuscript; available in PMC 2010 February 10.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
FIG. 4.
Food intake and energy expenditure. Daily food intake (A), cumulative food intake (B), oxygen
consumption (Vo2) (C), and diurnal oxygen consumption profile (D) of 24-week-old transgenic
and WT mice fed HFD (n = 8 per group) measured for 12 days in a comprehensive laboratory
animal monitoring system. Data are expressed as means ± SE. ■, WT-HFD; ●, transgenic-
HFD. For food intake, *P < 0.05 between genotypes. For oxygen consumption, ****P < 0.0001
between genotypes by mixed model analysis.
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FIG. 5.
Glucose tolerance and insulin sensitivity. Plasma glucose (A) and serum insulin (B) after an
overnight fast in 20-week-old transgenic and WT mice (n = 18–22 per group). Data are
expressed as means ± SE. C: Glucose tolerance test. Glucose (1 g/kg) was administered
intraperitoneally after an overnight fast to 16-week-old transgenic and WT mice fed chow or
HFD (n = 10 per group). Data are expressed as means ± SE. D: Insulin tolerance test. Insulin
(1.125 units/kg) was administered intraperitoneally after a 6-h fast to 21-week-old transgenic
and WT mice fed chow or HFD (n = 18–22 per group). Values are expressed as means ± SE
of percent initial value. The initial decrement from 0 to 15 min after insulin injection for WT-
HFD and transgenic-HFD groups are indicated (inset). □, WT-chow; ○, transgenic-chow; ■,
WT-HFD; ●, transgenic-HFD. *P < 0.05, **P < 0.01, and ***P < 0.001 between genotypes
on a given diet; #P < 0.05, ##P < 0.01, and ###P < 0.001 between diet groups for a given
genotype.
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TABLE 1
Gene expression in SCAT
WT-chow Transgenic-chow WT-HFD Transgenic-HFD
m11βHSD1 100 ± 11 110 ± 8 42 ± 7† 46 ± 8‡
GRα 100 ± 7 140 ± 23 79 ± 13 130 ± 28
Soluble phosphenolpyruvate carboxykinase 100 ± 8 97 ± 13 59 ± 4†* 105 ± 20
Adiponectin 100 ± 10 83 ± 14 72 ± 7#* 144 ± 6
PPARγ 100 ± 7 101 ± 17 82 ± 6* 134 ± 23
Uncoupling protein 2 100 ± 13 122 ± 16 209 ± 14‡* 325 ± 47#
Leptin 100 ± 19 118 ± 27 389 ± 29‡** 225 ± 40†
Resistin 100 ± 10 114 ± 20 217 ± 21‡* 150 ± 19
Tumor necrosis factor-α 100 ± 22 85 ± 19 124 ± 17 89 ± 16
Data are means ± SE. Gene expression in SCAT of 24-week-old mice (n = 10 per group) using quantitative real-time PCR. Data are normalized to
18S and presented as percentage of WT-chow control.
*
P < 0.05,
**
P < 0.01 between genotypes on a given diet;
#
P < 0.05,
†
P < 0.001,
‡
P < 0.0001 between diet for a given genotype.
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TABLE 2
Systemic indices of glucocorticoid exposure
WT-chow Transgenic-chow WT-HFD Transgenic-HFD
Serum corticosterone (ng/ml)
 (male, 10 weeks old, n = 8) 17.0 ± 13.5 18.2 ± 23.3 — —
Thymic weight (mg)
 (male, 10 weeks old, n = 8) 89.9 ± 2.0 88.5 ± 2.0 — —
Adrenal weight (mg)
 (male, 24 weeks old, n = 10) 3.21 ± 0.18 3.23 ± 0.21 3.65 ± 0.15 3.47 ± 0.10
Bone mineral density (mg/cm2)
 (male, 24 weeks old, n = 10) 524. ± 3 530 ± 3 543 ± 2 535 ± 5
Lean body mass (g)
 (male, 24 weeks old, n = 10) 25.1 ± 0.3 25.7 ± 0.3 26.7 ± 0.3 26.3 ± 0.4
Naso-anal length (cm)
 (male, 24 weeks old, n = 10) 10.0 ± 0.04 9.9 ± 0.03 10.3 ± 0.10 10.2 ± 0.10
Data are means ± SE.
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